Precision BioSciences Announces Allowance of Eleventh U.S. Patent Application Related to Genome Editing Nucleases

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--

Precision BioSciences, Inc., a leader in the field of genome engineering, today announced that the United States Patent and Trademark Office has issued a Notice of Allowance for U.S. Patent Application 13/457,041 (the 041 Application). The allowed claims relate to materials and substitutions used for the creation of enzymes capable of modifying endogenous locations within a complex genome. These materials and substitutions constitute an important aspect of Precisions genome engineering technologies, known collectively as the Directed Nuclease Editor or DNE.

Precisions DNE technology allows for highly precise gene editing with engineered nucleases, a technique named Method of the Year by Nature Methods. The Notice of Allowance will further augment Precisions ability to protect and capitalize on this important biological tool. Upon issuance of the 041 Application, Precision will control a patent estate consisting of eleven foundational genome engineering patents in the U.S. and one in Europe. The 041 Application is expected to issue as U.S. Patent No. 8,304,222 on November 6, 2012.

We are pleased that the U.S. Patent Office continues to recognize our novel contributions to the genome engineering field, stated Derek Jantz, co-inventor and Precision BioSciences Vice President of Scientific Development. This patent will allow us to protect yet another valuable aspect of our nuclease technology.

About Precision BioSciences

Precision BioSciences mission is to continually provide, improve, and enable the worlds most powerful genome engineering technology. Precisions proprietary Directed Nuclease EditorTM (DNE) technology enables the production of genome editing enzymes that can insert, remove, modify, and regulate essentially any gene in mammalian or plant cells.

Precision BioSciences vision is to be the conduit through which the worlds greatest genome engineering challenges are solved. Precision has successfully utilized its DNE technology to create innovative products in partnerships with many of the worlds largest biopharmaceutical, agbiotech, and animal research firms. Internally, Precision is developing applications of DNE in biological production and human therapeutics. For additional information, please visit http://www.precisionbiosciences.com.

Go here to see the original:
Precision BioSciences Announces Allowance of Eleventh U.S. Patent Application Related to Genome Editing Nucleases